Using dual-color reporters in C. elegans, the study shows maternal H3K9 methyltransferases MET-2 and SET-25 antagonistically regulate autosomal random monoallelic expression initiated in the early embryo
0:00Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. You know, we often attribute who we are, our health, our longevity, even how we react to medicine to this, well, this really clear split.
0:17It's either genetics or it's our environment. And that seems to cover everything, doesn't it? It feels like a complete explanation. For the most part, yes. It accounts for the vast majority of variation.
0:26But if you talk to cell biologists or developmental geneticists, they'll bring up this really challenging paradox, intrinsic biological variation. Right. The 3rd component, the one we rarely discuss. I mean, you can imagine 2 mice, right?
0:40Genetically identical, they're in the exact same cage eating the same food under perfectly controlled conditions, and yet one might develop cancer 2 years before the other, or one reacts powerfully to a drug, and the other, well, barely responds at all.
0:52And that is the critical insight here. Even with 0 genetic difference, an absolutely 0 environmental difference. You still see these vast, measurable variations. This variability. It comes down to a kind of molecular coin flip, a random, epigenetic decision.
1:09A decision that dictates whether a gene is turned on or off in a line of cells. Exactly. And the stakes for that, that Randall choice couldn't be higher for health. Think about dominant genetic diseases.
1:21The difference between someone who suffers from a condition and a family member who carries the exact same mutation, but is totally fine. It can come down to the single intrinsic choice made way back in early development.
1:33A process called autosomal, random, monolallic expression, or RMAE. And that's what we're getting into today. Right. Our deep dive today explores this groundbreaking work that figured out the developmental pathway controlling that biological choice, and specifically how it's all regulated by factors inherited from the mother right at the dawn of life.
1:53Okay, so let's get into the paper itself. We are focusing on the deep dive into the work published in nature communications, titled Maternal histone, methyl transfraces, antagonistically regulate autosomal, random mono-olellic expression, RMAE, in sea elegance.
2:09That title alone tells you we're dealing with some really fundamental biology here. Absolutely. And we have to give special recognition to the researchers who define this mechanism. The team was led by Brian Sands, sue R Yin, Chunko Oshima, and Alexander R.
2:24Mendenhall, mostly out of the University of Washington and Seattle. Their work has given us this incredibly clear developmental pathway that governs a core aspect of what makes us individuals. So let's start with the basics, RMAE.
2:38We all know genes come in pairs, one allel from each parent. Normally you'd think both copies are active. That's biolic expression, or B-A-E. So if we strip away the jargon, what really is R-A-E? It's a process where pretty much by chance, one of those 2 gene copies get silenced.
2:53It's probabilistic and it's persistent in that cell line. So once the decision is made, it sticks. It sticks. For that entire tissue, like the gut or part of the brain, the key is that it's on the autosomes, the nonsex chromosomes.
3:06And crucially, it's not passed down to the next generation. It's a temporary single generation kind of epigenetic decision. And the clinical significance of that is, it's just enormous. When you hear about genetic diseases with incomplete penetrance, you know, a patient has the bad gene but doesn't get sick.
3:26R MAE could be the missing link there. It absolutely can be. The paper actually highlights a classic case study. It was a family with a mutation in the PIT one gene, which affects growth. The grandmother and the father both carry this pathological alleal, but were completely healthy.
3:40But the daughter, who had the very same mutation, was profoundly affected. So what was the difference? The investigation showed that in the unaffected family members, the battle eel was randomly silenced.
3:50RMAE essentially rendered it harmless. But in the daughter, it was expressed. In the daughter, it was expressed, and that resulted in the disease. That one random decision determined her entire health outcome.
4:01Wow. So what kinds of genes are prone to this? Is it just anything? That's a great question. They found that genes subject to RMAE are highly enriched for roles in aging and chronic diseases, especially things related to immunity and cancer?
4:17And that's already having real world implications for treatment. In cancer, for example. Yes, in oncology, the silencing status of genes like BRCA1 and BRCA2 is already a huge deal for therapy. So for ovarian cancer, if you have a patient with a normal wild type copy of a BRCA gene, but that copy has been randomly silenced.
4:36By this process by MAE. Right. Then that patient actually responds really well to PRP inhibitors. Their cells act as if they have the genetic defect that the drug targets. Whereas a patient who expresses both copies doesn't respond.
4:48Exactly. So if you can figure out how that silencing is established, you open the door to therapies that could, you know, enforce or reverse it. And that need to understand the mechanism is what brought them to the humble worm.
4:59Okay, so let's talk about their model system. See elegance. It's such an elegant setup. The worm is transparent, and most importantly, it has a completely fixed mitotic cell lineage. That fixed lineage is so key.
5:15You know where every single a gold cell comes from. You can trace its history right back to a single progenitor cell in the early embryo. Which is perfect for tracking a decision made early in life. Perfect.
5:25So to see this process, which is usually invisible, they build this brilliant reporter system, they took a gene, HSP 90, which they knew was prone to RMAE. And they put in 2 synthetic copies. Right. They tagged one allel with a green fluorescent protein and the other with a red one.
5:41So you get a direct visual. A direct visual. If a cell expresses both copies, you get biologic expression or BAE. The red and green mix, and the cell nucleus just looks yellow. But if one allele gets silenced, then the cell will only glow red or only green.
5:55You are literally seeing the molecular coin flip happen in the worm's intestine. That's amazing. But seeing it is one thing they needed to quantify it. They used a metric called intrinsic noise. How does that work?
6:06So intrinsic noise is a mathematical way to measure how much the expression deviates from that perfect one-to-one yellow signal. If every cell is yellow, the intrinsic noise is very low. Because there's no randomness.
6:19No randomness, but if you see a ton of variation, lots of red only and green only cells, that means strong monoleic expression is happening, and your intrinsic noise score is high. It's a really clean way to measure the randomness.
6:33So high intrinsic noise means a strong RAE event. Exactly. And with that tool, they could finally do their screen. They used RNA interference to knock down genes they suspected were involved with chromatin.
6:45They focused on his stone methyl transfer phrases, the enzymes that write epigenetic marks. And right away, the results pointed to two major players working against each other. The 1st one they found was a protein called MB2.
6:57It's the worm version of a human protein called SETB one. And what was so unexpected was its job. When they got rid of Med 2, RMAE was significantly promoted. Wait, so getting rid of it made the silencing more like...
7:09So its normal job is to prevent the silencing. It's actually a negative regulator, pushing for that normal bileic expression. That is the crucial distinction, yes. Loss of meat 2 caused this huge spike in intrinsic noise.
7:22So then they looked for what could reverse that spike. And they found the antagonist, said 25. The molecular yin and yang. Pretty much. Set 25 is the worms version of the mammalian SUV 39 and G9A proteins.
7:36And losing set 25 had the exact opposite effect. It strongly prevented RAE. It pushed expression to extreme biolic, very low intrinsic noise. So you have meat T2 promoting the 2 color state, B-A-E, and set 25 promoting the one color silencing state, RME.
7:54A perfect antagonist. And they confirmed it was a real competition, right? They did beautifully. If you take a worm that's missing, Met 2, which should have extreme RME. All red and green cells. Right.
8:04And then you also knock down set 25. The whole phenotype just vanishes. Then it's back to yellow. It goes right back to the calm bioloic state. It's definitive proof of a tug of war. And they're not acting alone, are they?
8:15They have partners. They do. They identified smaller protein complexes. MT2 works with co-factors like LN65. And set 25 works with partners like HPL2. They're competing teams. And it's not just about them being physically present.
8:30It's about what they do, the actual chemistry. Exactly. The whole thing depends on their ability to write those epigenetic marks. They used CRISPR to make tiny point mutations in the catalytic set domains of both enzymes.
8:43The part that does the work. The part that does the work, and changing just a single amino acid was enough to completely break the enzyme's function, which proves the mechanism isn't structural. It's truly about actively competing to modify the histones.
8:56This brings us to the timing. The title said maternal, so how early is this battle decided? Extremely early. Through some clever reciprocal cross experiments, They figured out it's all controlled by the proteins the mother deposits into the egg.
9:09Not the DNA from the father. Not the DNA. It's the maternal protein contribution. And this critical competition between BT2 and set 25 happens in a single cell. Which one? The E-Cell. The progenitor for the entire adult intestine.
9:23And this is when the embryo is just 8 cells big. Eight cells. That's incredible. So the mother's stored proteins are deciding the fate for that entire adult tissue. Right. So even if the embryo inherits a perfectly good Met 2 gene from its father.
9:37If the maternal meat 2 protein wasn't there early enough. The damage is already done. The damage is done. Set T 25 is already won and enforce the silencing. And that decision gets passed down through cell division.
9:48Mitonically, yes. It creates this persistent locked in pattern in the adult tissues. But, and this is so important. It's not passed to the next generation. It's persistent, but it's not heritable. That distinction is so critical for understanding how this variation pops up new in every single generation, but was this MT2 versus set 25 battle, a kind of universal switch for all arm and me genes?
10:13No, and that's a key point. They found it was gene specific. So getting rid of Met2, increased RMAE for their HSP 90 reporter, and for another gene, but it had 0 effect on other genes like Fit2. So there must be other pathways, other tugs of war happening for different genes.
10:27Exactly. This HMT competition is one critical module, but not the only one. Okay, let's unpack the model. The actual molecular competition happening on the histone in that single e-cell. How are these 2 complexes using epigenetic marks to fight each other?
10:43So the model they proposed, which really synthesizes all the data nicely, is based on the different flavors of H3K9 mythylation marks. MT2 and its complex, they act as a transcriptional silencing repressor.
10:57Okay, break that down. It primarily deposits 83K9 ME1 or MeToo marks, mono or dimethylation, and these marks, while they are modifications, are often linked with permissive chromatin. They essentially license the gene for expression for BAE.
11:12And they block the other guy. And they actively inhibit the recruitment of the more powerful silencers set in 25. So MT2 is like putting down a sign that says transcription allowed here, heavy duty silencers, stay out.
11:22So said T25 is the heavy duty silencer. That's its function. If set 25 gets recruited 1st or if manages to kick MET off, it adds the fully repressive A3K9 ME3 mark, trimethylation. And that's the stop sign.
11:33That is a hard stop. It's a powerful blockade that physically stops transcription factors from binding. That's what gives you this silencing the RMAE. So the randomness, the actual coin flip, is just about who wins the race to the gene promoter in that one moment.
11:49Precisely. If the MET 2 complex wins, you get bileic expression. If said 25 wins, you get monololoic expression. And that outcome, once it's set in the ESL, is just locked in. It's locked in by mitosis.
12:02That's why they saw some animals lacking MET 2 with almost their entire intestine glowing one color. The decision was fixed at the 8 cell stage. The implications here go way beyond the worm. I mean, these genes, SCDB one and SUV 39 are conserved in humans.
12:17They are, which strongly suggests this antagonistic mechanism is a key part of how random monoloic expression works in mammals, too. It gives the whole field a new framework to work with. It really does.
12:28By finding one clear regulatory module, researchers can now hunt for the regulators of other RMEE prone genes much more efficiently. It shifts the work from just observing to actually understanding the mechanism.
12:40And the translational outlook is just huge. Understanding how these silencing states are naturally controlled is a massive step towards all specific therapies. Yes. I mean, imagine you have a patient with a silenced, healthy allele and an express pathological one.
12:54The goal would be to flip that. Exactly. The Holy Grail would be a drug that can specifically inhibit ST 25 at that location, letting MET 2 come in and turn on the healthy copy, or the reverse. Silencing an overactive cancer Jane.
13:08The ability to manipulate the outcome of that intrinsic early life coin flip, that really does feel like the future of personalized medicine. So to just summarize the central insight. The unpredictable part of our biological individuality, RMAE, is basically governed by an epigenetic tug of war.
13:27It's competition between 2 maternal histone metal transfer races, menti 2 and set 25. They battle it out in a single progenitor cell in the very early embryo. And the winner of that battle sets a gene expression pattern that lasts for life.
13:41It defines cellular identity, functional variability, and potentially your long term disease risk. And that leaves us with a pretty provocative final thought. It does. If your ultimate risk for a chronic disease can be decided randomly by maternal proteins in the 1st few cell divisions, how can we possibly develop early stage diagnostics, or maybe even interventions, that can assess and maybe influence those crucial initial epigenetic decisions before the bodies even fully formed?
14:08That developmental window. It's clearly where all the action is. This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description.
14:20If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating. If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about.
14:34Thanks for listening and join us next time as we explore more science, based by base.
